Product Licensing
Cancer-focused pharmaceutical company licenses heterocyclic hydrazones
Published in Cancer Weekly, November 1st, 2005
Vion Pharmaceuticals, Inc. (VION) announced that it had entered into an exclusive license agreement with a group of inventors from the Institute of Pharmacy and the Institute of Medical Chemistry and Biochemistry at the University of Innsbruck and Austria Wirtschaftsservice Gesellschaft m.b.H. (aws), related to a group of heterocyclic hydrazone compounds covered by patents or patent applications in North America and Europe.
Vion had previously announced the execution of a research collaboration and option agreement with the inventors and aws in December 2003. During the period of this agreement, Vion evaluated several compounds in preclinical studies and determined to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-11-01)
More Articles from Cancer Weekly
- Anticancer Drugs
TrxR inhibition contributes to cytotoxicity of anticancer compounds - Cancer Risk Factors
Susceptibility to carcinogens increased with early-life exposure - Cancer Therapy
Adjuvant chemotherapy proposed for stage II colorectal cancer - Leukemia
AMN107 performed better as inhibitor of Ph-positive leukemia than imatinib - Paclitaxel
Combination therapy had significant effect on reduction of prostate tumor volume - Alternative Surgery
Median sternotomy proposed as alternate approach to extrapleural pneumonectomy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
